Cyclothymic OCD: A distinct form?

Journal of Affective Disorders

Volumn 75, Issue 1, 2003, Pages 1-10

  Hantouche, E G ^a   Angst, J ^b   Demonfaucon, C ^c   Perugi, G ^d   Lancrenon, S ^e   Akiskal, H S ^f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^c AFTOC   (France)

^d Psychiatric Institute of Pisa   (Italy)

^e Sylia Stat   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comorbidity; Cyclothymia; Hypomania; Obsessive compulsive disorder; OCD French Association

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LITHIUM; NEUROLEPTIC AGENT;

ADULT; AGGRESSION; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; COMPULSION; CONTROLLED STUDY; CYCLOTHYMIA; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOMANIA; IMPULSIVENESS; MAJOR DEPRESSION; MALE; MANIA; MENTAL INSTABILITY; MENTAL PATIENT; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; SELF CONCEPT; SUICIDE ATTEMPT;

EID: 0038012660     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(02)00461-5     Document Type: Article

References (34)

1. Akiskal H.S., Pinto O. The evolving bipolar spectrum: prototypes I, II, III and IV. PCNA. 22:1999;517-534.
2. Akiskal H.S., Hantouche E.G., Bourgeois M.L., Azorin J.M., Sechter D., Allilaire J.F., Chatenet-Duchene L., Lancrenon S. Toward a refined phenomenology of DSM-IV mania: Combining clinician-assessment and self-report in the French EPIMAN study. J. Affect. Disord. 67:2001;89-96.
3. Akiskal H.S., Hantouche E.G., Lancrenon S. BP-II with and without cyclothymic temperament: "dark" and "sunny" expressions. J. Affect. Disord. 73:2003;49-57.
4. Allilaire J.F., Hantouche E.G., Sechter D., Bourgeois M.L., Azorin J.M., Lancrenon S., Chatenêt-Duchêne L., Akiskal H.S. Fréquence et aspects cliniques du trouble BP-II dans une étude multicentrique française: EPIDEP. Encephale. 27:2001;149-158.
5. Altman E. Rating scales for mania: is self-rating reliable? J. Affect. Disord. 50:1998;283-286.
6. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord. 50:1998;143-151.
7. Angst, J., Hantouche, E.G., 2002. The epidemiology of minor bipolar disorder and hypomania: new territory. In: Vieta, E. (Ed.), Hypomania, Aula Médica Bibliotecas, Madrid, pp. 13-31.
8. Ballet G. La mélancolie intermittente. Presse Med. 39:1902;459-462.
9. Berk M., Koopowitz L.E., Szabo C.P. Antidepressant-induced mania in OCD. Eur. Neuropsychopharmacol. 6:1996;9-11.
10. Chen Y.W., Dilsaver S.C. Comorbidity for OCD in bipolar and unipolar disorders. Psychiatry Res. 59:1995;57-64.
11. De H.L., Beuk N., Hoogenboom B., Dingemans P., Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J. Clin. Psychiatry. 63:2002;104-107.
12. Demonfaucon C., Hantouche E.G. Approche dimensionnelle des rapports entre TOC et bipolarité: interactions entre émotivité, impulsivité, lenteur et place centrale de la symétrie. Synapse. 180:2001;31-40.
13. Fitzgerald K.D., Stewart C.M., Tawile V., Rosenberg D.R. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J. Child. Adolesc. Psychopharmacol. 9:1999;115-123.
14. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can. J. Psychiatry. 46:2001;356-358.
15. Hantouche E.G., Akiskal H.S., Lancrenon S Allilaire J.F., Sechter D., Azorin J.M., Bourgeois M., Fraud J.P., Chatenet-Duchene L. Systematic clinical methodology for validating BP-II disorder: data in mid-stream from a French national study (EPIDEP). J. Affect. Disord. 50:1998;163-175.
16. Hantouche E.G., Akiskal H.S., Bourgeois M.L., Azorin J.M., Sechter D., Allilaire J.F., Chatenet-Duchene L., Lancrenon S. The feasibility of self-assessment of dysphoric mania in the French national EPIMAN study. J. Affect. Disord. 67:2001;97-103.
17. Hantouche E.G., Akiskal H.S., Demonfaucon C., Barrot I., Kochman F., Millet B., Lancrenon S., Allilaire J.F. Bipolarité cachée dans le trouble obsessionnel compulsif: enquête collaboratîve avec l'AFTOC. Ann. Med. Psychol. 160:2002;34-41.
18. Hantouche E.G., Kochman F., Demonfaucon C., Barrot I., Millet B., Lancrenon S., Akiskal H.S. TOC bipolaire: confirmation des résultats de l'enquête «ABC-TOC» dans deux populations de patients adhérents versus non adhérents à une association. Encephale. 28:2002;21-28.
19. Hantouche E.G., Angst J., Akiskal H.S. Factor structure of hypomania: Interrelationships with cyclothymia and soft bipolar spectrum. J. Affect. Disord. 73:2003;39-47.
20. Jacobsen F.M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J. Clin. Psychiatry. 56:1995;423-429.
21. Khullar A., Chue P., Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J. Psychiatry Neurosci. 26:2001;55-59.
22. Koran L.M., Ringold A.L., Elliott M.A. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry. 61:2000;514-517.
23. Lester D., Abdel-Khalek A.M. Manic-depression, suicidality, and obsessive-compulsive tendencies. Psychol. Rep. 85:1999;1100.
24. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry. 57:2000;794-801.
25. Mohr N., Vythilingum B., Emsley R.A., Stein D.J. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 17:2002;37-40.
26. Perugi G., Akiskal H.S., Pfanner C., Presta S., Gemignani A., Milanfranchi A., Lensi P., Ravagli S., Cassano G.B. The clinical impact of bipolar and unipolar affective comorbidity on obsessive-compulsive disorder. J. Affect. Disord. 46:1997;15-23.
27. Perugi G., Akiskal H.S., Gemignani A., Pfanner C., Presta S., Milanfranchi A., Lensi P., Ravagli S., Maremmani I., Cassano G.B. Episodic course in obsessive-compulsive disorder. Eur. Arch. Psychiatr. Clin. Neurosci. 248:1998;240-244.
28. Perugi G., Akiskal H.S., Ramacciotti S., Nassini S., Toni C., Milanfranchi A., Musetti L. Depressive comorbidity of panic, social phobia, and OCD re-examined: is there a bipolar II connection? J. Psychiatry Res. 33:1999;53-61.
29. Perugi, G., Toni, C., Frare, F., Travierso, C., Hantouche, E., Akiskal, H.S., 2003. Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcomes. J. Clin. Psychiatry, in press.
30. Pfanner C., Marazziti D., Dell'Osso L., Presta S., Gemignani A., Milanfranchi A., Cassano G.B. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int. Clin. Psychopharmacol. 15:2000;297-301.
31. Ravizza L., Barzega G., Bellino S., Bogetto F., Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol. Bull. 32:1996;677-682.
32. Saxena S., Wang D., Bystritsky A., Baxter L.R. Jr. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J. Clin. Psychiatry. 57:1996;303-306.
33. Stein D.J., Bouwer C., Hawkridge S., Emsley R.A. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry. 58:1997;119-122.
34. Weiss E.L., Potenza M.N., McDougle C.J., Epperson C.N. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J. Clin. Psychiatry. 60:1999;524-527.